Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nefazodone: single versus twice daily dose

J C Voris1, G N Shaurette, P S Sebastian

  • 1Department of Clinical Pharmacy, College of Pharmacy, University of South Carolina, Dorn Veterans Hospital, Columbia 29209-1639, USA.

Pharmacotherapy
|April 17, 1998
PubMed
Summary

Nefazodone, a treatment for major depression, may be as effective when taken once daily at bedtime compared to twice daily. This dosing regimen also appears to reduce daytime drowsiness in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The link between carotid artery stenosis and outcomes in patients with refractory out-of-hospital cardiac arrest.

Resuscitation·2024
Same author

Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities.

Journal of clinical psychology·1999
Same author

Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals.

Psychiatric services (Washington, D.C.)·1999
Same author

Money as a tool to extinguish conditioned responses to cocaine in addicts.

Journal of clinical psychology·1998
Same author

Daily cocaine craving in a 3-week inpatient treatment program.

Journal of clinical psychology·1993
Same author

Neuroleptic malignant syndrome associated with carbamazepine.

Southern medical journal·1991

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is a prevalent and debilitating mental health condition.
  • Current treatment guidelines for nefazodone involve twice-daily dosing.
  • Optimizing antidepressant dosing regimens is crucial for improving patient adherence and outcomes.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of once-daily, bedtime dosing of nefazodone in men with major depression.
  • To compare the effectiveness of once-daily nefazodone with the standard twice-daily regimen.
  • To assess the impact of nefazodone dosing on daytime drowsiness.

Main Methods:

  • A pilot study involving six male participants diagnosed with major depression.
  • Nefazodone was administered at dosages of at least 400 mg/day, either twice daily or once daily at bedtime.

Related Experiment Videos

  • Depression severity was assessed using the Hamilton Depression Rating Scale (self-report version) at baseline and 4 weeks.
  • Daytime drowsiness was measured using a visual analog side effect scale at 4 weeks.

    • Main Results:

    • Nefazodone administered once daily at bedtime demonstrated comparable efficacy to the twice-daily regimen in reducing depressive symptoms.
    • Participants receiving once-daily, bedtime nefazodone reported less daytime drowsiness.
    • All participants received a minimum dosage of 400 mg/day of nefazodone.

    Conclusions:

    • Once-daily, bedtime dosing of nefazodone may be a viable alternative to twice-daily administration for major depression.
    • This alternative regimen could potentially improve treatment adherence and reduce side effects like daytime drowsiness.
    • Further research with larger sample sizes is warranted to confirm these findings.